E.g., 03/28/2024
E.g., 03/28/2024

bioMérieux and GSK Sign Theranostics Agreement to Develop Predictive Test for Selecting Breast Cancer Treatment

17 November, 2009

bioMérieux has signed an agreement with GlaxoSmithKline to develop a predictive test to help clinicians select the most appropriate treatment for different segments of breast cancer patients. This test, based on emerging biomarkers, will be intended for use in both adjuvant and metastatic breast cancer settings, subject to regulatory approvals. Over 500,000 new cases of breast cancer are diagnosed each year in the US and Europe alone and predictive tests have been shown to improve outcomes for these patients.

bioMérieux's VIDAS System Simplifies the Detection of Salmonella and E. coli O157 Including H7 Strains for the Meat Industry

10 November, 2009

50_078minividasblue_thumb19.jpg bioMérieux, a world leader in the field of in vitro diagnostics, today announced that VIDAS® Salmonella Xpress (SLMX) and VIDAS® UP E. coli O157 (Including H7) kits have been validated by AFNOR Certification according to the ISO 16140 standard. These validations cover the testing of raw beef and veal.

bioMérieux Unveils its Groundbreaking Culture Media Range for Sterility Control of Aseptic Pharmaceutical Plants

07 November, 2009

New range will simplify testing for the pharmaceutical industry.

Alain Pluquet's Appointment

03 November, 2009

A world leader in the field of in vitro diagnostics, bioMérieux has appointed Alain Pluquet to the newly created position of Chief Technology Officer (CTO).

bioMérieux Adds Methicillin-Resistant Staphylococcus Aureus (MRSA) Screening Tool to its Arsenal

28 October, 2009

New chromogenic media provides cost-effective MRSA identification for hospitals and labs

bioMérieux - Business Review for the Nine Months Ended September 30, 2009

20 October, 2009

bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the nine months ended September 30, 2009.

Antibiotic-Resistant Infections Cost the U.S. Healthcare System in Excess of $20 Billion Annually

19 October, 2009

In addition, these avoidable infections result in more than $35 billion in societal costs and more than 8 million additional days spent in the hospital

Guidon Partners with bioMérieux to Provide Lean Assessment Services to Microbiology Laboratories

19 October, 2009

Guidon Performance Solutions, a leading provider of Lean and Six Sigma performance management consulting to the service sector, today announced a partnership with bioMérieux, a world leader in the field of in vitro diagnostics, to provide Lean Six Sigma workflow assessment services to microbiology laboratories.

bioMérieux Launches Solutions to Manage the Antimicrobial Resistance Threat (S.M.A.R.T.) Campaign

14 September, 2009

Antimicrobial resistance and the spread of Multi-Drug Resistant Organisms (MDRO) have become worldwide public health issues

Pioneering Diagnostics